Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)

This study has been completed.
Information provided by (Responsible Party):
Celladon Corporation Identifier:
First received: July 16, 2012
Last updated: February 25, 2016
Last verified: February 2016